[ad_1]
Geneva, Switzerland, September 19, 2024 – 6:30 PM CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the drivers of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that new findings on the anti-neurodegenerative effect of Temelimab in a model of MS were presented as a poster at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in Copenhagen, Denmark. The presentation was given by Dr. Joel Gruchot from the group of Prof. Patrick Küry at the Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany, in collaboration with the Department of Neurology, University of Bern, Switzerland, and the Institute of Pharmacology and Toxicology, University of Zurich, Switzerland.
[ad_2]
Source link -86